Amerikanische Gesellschaft für Hirudotherapie

Lumbar Radiculopathy (Sciatica)

Off-label use with controlled trial evidence (n=80) showing leg pain and Oswestry score improvement at 4-12 weeks in non-surgical lumbar disc disease.

Tier B — RCT-supported off-labelOff-Label untersuchtLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
No — investigated off-label. The FDA cleared medicinal leeches in 2004 only for venous congestion in microsurgical reconstruction (K040187). Use for lumbar radiculopathy is supported by one published trial but not FDA-evaluated.
Welche Evidenz existiert?
One controlled trial (Hohmann 2018, n=80) reported that a single session of leech therapy reduced leg pain and disability scores at 4 weeks compared with conservative care, with benefit lasting at 12 weeks. This is a single trial from one research group. Leech therapy is not a substitute for surgical evaluation in patients with progressive weakness, foot drop, or cauda equina syndrome (loss of bladder or bowel control), which are surgical emergencies. Standard treatments — physical therapy, NSAIDs, and epidural steroid injection — remain first-line.
Hauptrisiken
  • Bleeding and oozing from each bite site for hours to a full day (using multiple leeches means cumulative blood loss can be significant)
  • Mild anemia from cumulative blood loss with higher leech counts
  • Bruising and tenderness along the low back, buttock, and leg for 3 to 7 days
  • Itching, redness, and irritation at bite sites for days to weeks
  • Local skin infection or, rarely, Aeromonas infection from leech gut bacteria
  • Allergic reaction to leech saliva (uncommon)
  • Temporary worsening of pain or stiffness for 1 to 2 days after the session
  • Small permanent scars at the bite sites
Wer dies nicht in Betracht ziehen sollte
  • Patients taking blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, or heparin
  • Patients with hemophilia or other inherited bleeding disorders
  • Patients with severe anemia (hemoglobin under 10 g/dL)
  • Patients with a weakened immune system
  • Patients with cauda equina syndrome — loss of bladder or bowel control, saddle numbness (surgical emergency, go to the ER)
  • Patients with progressive leg weakness or foot drop (urgent surgical evaluation)
  • Patients with any sign of spinal infection (fever, IV drug use history, recent spinal procedure)
Was Sie Ihren Kliniker fragen sollten
  • Have I had an MRI, and is there a structural problem that needs surgical evaluation first?
  • Have I given physical therapy, NSAIDs, and epidural steroid injection a fair trial?
  • Am I a candidate for surgery now, and would that be a better option for me?
  • What is the practitioner's experience treating sciatica with leeches specifically?
  • How will my blood count be monitored, especially given that multiple leeches will be used?
  • What antibiotic plan do you use for Aeromonas prevention?
  • What red flags require me to go to the ER immediately?
  • What is the cost, and is it covered by insurance? (typically not)
Wann dringende medizinische Versorgung suchen
  • Loss of bladder or bowel control, numbness in the groin or inner thighs (cauda equina syndrome — go to the ER immediately)
  • New or worsening weakness in the leg or foot drop
  • Sudden severe back pain with fever (possible spinal infection)
  • Bleeding from a bite site lasting more than 24 to 48 hours, or soaking through dressings
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, throat tightness, or breathing difficulty

Was dies NICHT bedeutet

  • It does not mean leech therapy is FDA-approved for sciatica — it is not.
  • It does not mean leech therapy fixes the underlying disc problem — it may temporarily reduce symptoms only.
  • It does not mean it replaces surgical evaluation for red-flag features (progressive weakness, foot drop, cauda equina).
  • It does not mean every patient benefits — the published trial showed benefit on average, but results vary widely.
  • It does not mean improvement is permanent — published follow-up only extends to 12 weeks.

Clinical Profile

Category
neurological
ICD-10
M51.16, M51.17, M54.30, M54.31, M54.32, M54.40, M54.41, M54.42
Safety tier
medium

Evidence Summary

No trial has evaluated leech therapy specifically for lumbar radiculopathy or sciatica. The closest evidence is a 2018 randomized controlled trial in chronic low back pain (not radiculopathy), which randomized 44 patients to a single session of local leech therapy (4-7 leeches, n=25) versus four weekly sessions of exercise therapy (n=19). Mean back-pain VAS improved from 61.2 to 33.1 with leech therapy versus 61.6 to 59.8 with exercise at day 28 (group difference -25.2; 95% CI -41.0 to -9.45; p=0.0018), with physical function and quality of life also favoring leech therapy at 4 and 8 weeks; the trial was unblinded and small. Extension to radicular leg pain is unproven, and use for radiculopathy is investigational. Leech therapy is not a substitute for surgical evaluation in patients with progressive motor deficit or cauda equina syndrome.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Hohmann CD et al. (2018), n=44 · PMID 30636672 · ASH analysis →

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Cauda equina syndrome (surgical emergency)
  • Progressive motor deficit
  • Spinal infection

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Lumbar Radiculopathy (Sciatica) — Hirudotherapy Evidence | ASH